Tuesday 25 September 2018

Advanced Hepatocellular Carcinoma in A Scottish Population – Current Experience and the Future: CTGH- Lupine Publishers

Sorafenib is the current first line standard of care in patients with advanced hepatocellular carcinoma (HCC). Several other drugs are emerging as efficacious agents in this setting. This article will outline our current real-world experience with sorafenib in a Scottish population as well as discuss the evidence behind new potential therapies.

No comments:

Post a Comment

Note: only a member of this blog may post a comment.